TDP-43 Co-pathology in Corticobasal Syndrome

Overview

While corticobasal syndrome (CBS) is classically characterized as a 4-repeat (4R) tauopathy, a significant subset of cases exhibit TDP-43 pathology. This overlap between tauopathies and TDP-43 proteinopathies has important implications for understanding disease heterogeneity, clinical presentation, and therapeutic approaches. Research from 2025, including studies by Murakami et al., has clarified the frequency and significance of TDP-43 pathology in CBS^{1Frontotemporal Lobar degeneration with TDP-43 presenting as PSP syndrome (2025)2025 · PMID 40635087Open reference}.

TDP-43 (TAR DNA-binding protein 43) is a 414-amino acid nuclear protein encoded by the TARDBP gene that plays critical roles in RNA splicing, transport, and stability. In neurodegenerative diseases, TDP-43 undergoes pathological transformation characterized by phosphorylation, ubiquitination, cleavage into C-terminal fragments, and aggregation into cytoplasmic inclusions. This page comprehensively covers TDP-43 co-pathology mechanisms in CBS.

TDP-43 Pathology in CBS: Current Understanding

Frequency and Distribution

TDP-43 pathology in CBS is more common than traditionally recognized:

The distribution of TDP-43 pathology in CBS includes:

• Motor cortex (especially layer II)

• Basal ganglia (putamen, globus pallidus)

• Substantia nigra

• Hippocampus (in cases with cognitive impairment)

• Spinal cord anterior horns

Clinical Correlations

The presence of TDP-43 pathology influences the clinical presentation of CBS^{1Frontotemporal Lobar degeneration with TDP-43 presenting as PSP syndrome (2025)2025 · PMID 40635087Open reference}:

1. Cognitive Impairment: Cases with significant TDP-43 pathology show more prominent cognitive decline, often resembling frontotemporal dementia

2. Language Symptoms: Greater prevalence of aphasia and speech apraxia in CBS with TDP-43

3. Psychiatric Features: Increased frequency of behavioral changes

4. Disease Progression: Mixed pathology may be associated with more rapid progression

Mechanisms of TDP-43 Pathology in CBS

Pathological Mechanisms

The mechanisms linking TDP-43 pathology to CBS include:

flowchart TD
    A["Genetic Factors"]  -->  B["TDP-43 Mislocalization"]
    C["Stress Responses"]  -->  B
    D["Tau Pathology"]  -->  B

    B  -->  E["Nuclear Clearance"]
    B  -->  F["Cytoplasmic Inclusions"]

    E  -->  G["RNA Processing Dysregulation"]
    F  -->  H["Neuronal Dysfunction"]

    G  -->  I["Cell Death"]
    H  -->  I

    I  -->  J["Cognitive/Motor Symptoms"]

Genetic Contributions

Several genetic factors influence TDP-43 pathology in CBS:

• GRN (Progranulin) Mutations: Associated with increased TDP-43 pathology

• C9orf72 Expansions: Can present with CBS phenotype with TDP-43 pathology

• TMEM106B Variants: Modify TDP-43 pathology risk

The interaction between tau and TDP-43 pathologies is complex, with evidence suggesting bidirectional relationships.

TDP-43 Inclusion Types in CBS

The pathological manifestations of TDP-43 in CBS are heterogeneous and include multiple inclusion types:

1. Cytoplasmic Inclusions

2. Neuronal Inclusions

• Neuronal cytoplasmic inclusions (NCIs): Most common type, found in pyramidal neurons

• Neuronal intranuclear inclusions (NIIs): Less common, associated with specific genetic forms

• Dystrophic neurites: Abnormal neuritic processes containing TDP-43

3. Glial Inclusions

• Astrocytic inclusions: TDP-43 positive astrocytes in affected regions

• Oligodendroglial inclusions: Less frequently observed

4. Morphological Variants

The morphology of TDP-43 inclusions in CBS differs from classical ALS/FTD patterns:

• More diffuse cytoplasmic staining

• Less prominent skein-like inclusions compared to ALS

• More frequent co-localization with tau pathology

Relationship Between Tau and TDP-43 Pathology

Bidirectional Interaction Mechanisms

The relationship between tau and TDP-43 in CBS is complex and involves multiple interaction pathways:

flowchart TD
    A["Tau Pathology"] --> B["Axonal Transport Dysfunction"]
    B --> C["TDP-43 Mislocalization"]
    D["Stress Granules"] --> C
    E["RNA Processing Defects"] --> C
    C --> F["Cytoplasmic TDP-43 Accumulation"]
    F --> G["Impaired Autophagy"]
    G --> H["TDP-43 Aggregation"]
    A --> I["Protein Homeostasis Disruption"]
    I --> H
    H --> J[" neuronal dysfunction"]

Mechanisms of Tau-TDP-43 Co-aggregation

1. Axonal transport impairment: Hyperphosphorylated tau disrupts microtubule-based transport, leading to TDP-43 mislocalization ^{2Tau pathology induces TDP-43 mislocalization in neurons (2024)2024 · DOI 10.1002/alz.14389Open reference}

2. Shared vulnerability factors: Both pathologies target neurons with high metabolic demands

3. Protein homeostasis disruption: Tau pathology impairs ubiquitin-proteasome and autophagy systems

4. Stress granule sequestration: Both proteins can be recruited to stress granules

Regional Distribution Patterns

The anatomical distribution of tau and TDP-43 pathology often shows complementary patterns:

TDP-43 Aggregation Mechanisms

Molecular Pathways to Aggregation

1. Nuclear Clearance and Cytoplasmic Mislocalization

TDP-43 normally resides in the nucleus but in disease states accumulates in the cytoplasm. Key mechanisms include:

• Nuclear import defects: Reduced importin-α/β function

• Nuclear export dysregulation: Enhanced CRM1-mediated export

• Stress granule formation: TDP-43 seeded into stress granules

2. Post-translational Modifications

3. Cryo-EM Structures

Recent cryo-EM studies have elucidated TDP-43 filament structures in CBS and related disorders ^{3Cryo-EM structures of TDP-43 filaments from ALS and FTD (2022)2022 · DOI 10.1038/s41586-022-04431-7Open reference}:

• Type A filaments: Left-handed helical filaments, 10-12 nm diameter

• Type B filaments: Right-handed helical filaments, 10-15 nm diameter

• Core structure: Residues 274-331 form the filament core

• Phosphorylation: Ser409/410 in the disordered outer shell

Aggregation Kinetics

flowchart LR
    A["Native TDP-43"] --> B["Monomeric Misfolding"]
    B --> C["Nuclear Clearance"]
    C --> D["Soluble Oligomers"]
    D --> E["Insoluble Filaments"]
    E --> F["Large Inclusions"]
    B -.-> G["Stress Granule Sequestration"]
    G --> D

Comparison with ALS/FTD TDP-43 Pathology

Shared Features

Distinctive Features in CBS

1. Co-pathology with tau: CBS shows significant tau co-occurrence (~30-40%), whereas ALS is typically tau-negative

2. Inclusion morphology: CBS has fewer skein-like inclusions than ALS

3. Regional distribution: More prominent basal ganglia involvement in CBS

4. Genetic associations: Different spectrum of causal genes

Pathological Staging

Impact on Neuronal Dysfunction

Mechanisms of TDP-43-Mediated Neurotoxicity

1. Loss of Nuclear Function

• Impaired RNA splicing (exon skipping, intron retention)

• Disrupted RNA transport and localization

• Altered gene expression programs

2. Gain of Cytoplasmic Function

• Stress granule pathology

• Translation dysregulation

• Mitochondrial dysfunction

• Axonal transport defects

3. Cellular Vulnerability Factors

Clinical Manifestations

The presence of TDP-43 pathology in CBS correlates with:

1. Cognitive impairment: More prominent than in pure tauopathy cases

2. Language deficits: Aphasia and speech apraxia

3. Behavioral changes: Disinhibition, apathy

4. Disease progression: Mixed pathology associated with faster decline

Genetic Factors Modifying TDP-43 in CBS

Major Genetic Contributors

GRN (Progranulin)

GRN mutations cause haploinsufficiency leading to reduced progranulin levels^{4Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 (2006)2006 · PMID 16437542Open reference}:

• Mechanism: Progranulin deficiency impairs lysosomal function

• Result: TDP-43 accumulates due to impaired clearance

• Pathology: Type A TDP-43 inclusions

C9orf72 Repeat Expansions

C9orf72 hexanucleotide repeat expansions^{5Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 gene in frontotemporal dementia and amyotrophic lateral sclerosis (2011)2011 · PMID 21944778Open reference}:

• Mechanism: RNA foci formation and dipeptide repeat proteins

• Result: TDP-43 pathology as downstream effect

• Pathology: Type B TDP-43 inclusions

TMEM106B Variants

TMEM106B acts as a modifier^{6Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010)2010 · PMID 20220177Open reference}:

• Risk variant: TMEM106B haplotypes affect lysosomal function

• Effect: Modulates TDP-43 pathology severity

• Interaction: Effects modified by GRN status

TDP-43 Classification Systems

Biomarker-Based Classification

A 2025 study by Palleis et al. established a biomarker-based classification system for CBS that incorporates TDP-43 pathology^{7A Biomarker-Based Classification of Corticobasal Syndrome (2025)2025 · PMID 41048081Open reference}:

This classification has diagnostic and prognostic implications.

Diagnostic Implications

Clinical-Pathological Correlations

Understanding TDP-43 pathology in CBS has practical implications:

1. Anticipating Clinical Course: Patients with TDP-43-predominant pathology may show faster cognitive decline

2. Genetic Testing: Presence of TDP-43 pathology may warrant testing for GRN and C9orf72 mutations

3. Therapeutic Considerations: TDP-43-targeting therapies may benefit specific patient subgroups

Biomarkers for TDP-43 Pathology

Current and emerging biomarkers include:

• Neurofilament Light Chain (NfL): Elevated in CSF and blood; higher levels in TDP-43 cases

• TDP-43 CSF Levels: Under investigation as direct marker

• PET Tracers: Emerging tau PET may help differentiate pathologies

Therapeutic Implications

Targeting TDP-43 Pathology

Therapeutic strategies for TDP-43 in CBS include^{8Progranulin Therapy for Neurodegeneration}:

1. RNA-Targeting Therapies: Antisense oligonucleotides targeting TDP-43 mRNA

2. Protein Clearance: Enhancing autophagy and ubiquitin-proteasome system

3. Reducing Stress Granule Formation: Small molecules targeting stress granule dynamics

Progranulin-Based Therapies

Given the association between GRN mutations and TDP-43 pathology^{9Progranulin (PGRN) - Biomarker}:

• Recombinant Progranulin: Currently in clinical trials for FTD-GRN

• Gene Therapy: AAV-mediated PGRN delivery under investigation

• Small Molecule Enhancers: Compounds that increase progranulin expression

Relationship to Other CBS Mechanisms

• LRRK2 in CBS and 4R Tauopathies — Shared mechanisms with other 4R tauopathies

• CBS vs PSP: Comparative Mechanism Analysis — TDP-43 frequency differences

• GRN — Progranulin — Genetic factors in TDP-43 pathology

• C9orf72 — Hexanucleotide repeat expansions with TDP-43 pathology

• TARDBP — TDP-43 encoding gene

• TDP-43 Proteinopathy — General TDP-43 mechanisms

• Progranulin Therapy — Therapeutic approaches

Summary

TDP-43 pathology is present in a substantial minority of CBS cases, influencing clinical presentation, disease progression, and therapeutic approaches. The 2025 research by Murakami et al. and others has clarified that:

1. Approximately 40-50% of CBS cases have some degree of TDP-43 pathology

2. Mixed pathology is common and influences clinical phenotype

3. Genetic factors (GRN, C9orf72, TMEM106B) modify risk

4. Biomarker-based classification can predict underlying pathology

5. Therapeutic implications include TDP-43-targeted approaches for appropriate patients

Understanding the TDP-43 component of CBS is essential for precision medicine approaches to this heterogeneous disorder.

See Also

• TARDBP

• GRN

• C9orf72

• TMEM106B

• LRRK2 in CBS and 4R Tauopathies

• CBS vs PSP: Comparative Mechanism Analysis

• GRN — Progranulin

• TDP-43 Proteinopathy

• Progranulin Therapy

External Links

• PubMed

• KEGG Pathways